Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Cited by (1,000)

Items 301–400 of 1,000

1. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective
   Andrzej J. Jakubowiak, Marco Campioni, Ágnes Benedict, Ivan Houisse, Eszter Tichy, Andromachi Giannopoulou, Sanjay Kumar Aggarwal, Beth Barber, Sumeet S. Panjabi · 2016 · Journal of Medical Economics
2. The molecular mechanism of thalidomide analogs in hematologic malignancies
   Stefanie Lindner, Jan Krönke · 2016 · Journal of Molecular Medicine
3. Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States
   Josh John Carlson, Gregory F. Guzauskas, Richard H. Chapman, Patricia G. Synnott, Shanshan Liu, Elizabeth T. Russo, Steven D. Pearson, Elizabeth Brouwer, Daniel A. Ollendorf · 2017 · Journal of Managed Care & Specialty Pharmacy
4. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone
   Ulrike Klein, Florentina Kosely, Jens Hillengaß, Michael Hundemer, Stefan Schmitt, Kai Neben, Thomas M. Moehler, Ute Hegenbart, Anthony Dick Ho, Hartmut Goldschmidt · 2008 · Annals of Hematology
5. Multiple myeloma with extramedullary disease
   Albert Oriol · 2011 · Advances in Therapy
6. Clarithromycin (Biaxin)‐lenalidomide‐low‐dose dexamethasone (BiRd) versus lenalidomide‐low‐dose dexamethasone (Rd) for newly diagnosed myeloma
   Francesca Gay, S. Vincent Rajkumar, Morton Coleman, Shaji Kunnathu Kumar, Tomer Martin Mark, Angela A. Dispenzieri, Roger Niles Pearse, Morie Abraham Gertz, John Paul Leonard, Martha Q. Lacy et al. · 2010 · American Journal of Hematology
7. Multiple myeloma in the very elderly patient: challenges and solutions
   Andrew J King, Toby Andrew Eyre, Faye Amelia Sharpley, Caroline S. Watson, Karthik Ramasamy, John Willan · 2016 · Clinical Interventions in Aging
8. Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel
   Valerio De Stefano, Alessandra Larocca, Monica Carpenedo, Michèle Cavo, Francesco Di Raimondo, Anna Falanga, Massimo Offidani, Maria Teresa Petrucci, Marco Ruggeri, Roberto Mario Santi et al. · 2022 · Haematologica
9. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches
   Monika Martha Engelhardt, Martina Kleber, Josefina Udi, Ralph Wäsch, Andrew G Spencer, Francesca F. Patriarca, Stefan Tobias Knop, Benedetto Bruno, Martin Gramatzki, Fortunato Morabito et al. · 2010 · Leukemia & lymphoma/Leukemia and lymphoma
10. Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients
    Hakan Kaya, Ben Peressini, Irfan Jawed, Danko Martincic, Ameer L. Elaimy, Wayne T. Lamoreaux, Robert K. Fairbanks, Kevin Austin Weeks, Christopher M. Lee · 2011 · International Journal of Hematology
11. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients
    Nicolaus Martin Kröger, Tatjana Zabelina, Evgeny Klyuchnikov, Martin H. Kropff, K-H Pflüger, Andreas Burchert, Thomas Stübig, Christine Wolschke, Francis Ayuk, York Hildebrandt et al. · 2012 · Bone Marrow Transplantation
12. Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma
    Michèle Cavo, Francesco Di Raimondo, Elena Zamagni, Francesca F. Patriarca, Paola Tacchetti, Antonio Francesco Casulli, Silvestro Volpe, Giulia Perrone, Antonio Ledda, Michela Ceccolini et al. · 2009 · Journal of Clinical Oncology
13. Treatment of Relapsed/Refractory Multiple Myeloma
    Efstathios Kastritis, Antonio Palumbo, Meletios Athanasios Dimopoulos · 2009 · Seminars in Hematology
14. New Insights into Therapeutic Targets in Myeloma
    Kenneth Carl Anderson · 2011 · Hematology
15. The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma
    Susanne Schmitz, Áine Maguire, James Morris, Kai Ruggeri, Elisa Haller, Isla L. Kuhn, Joy Leahy, Natalia Homer, Ayesha Khan, Jack Bowden et al. · 2018 · BMC Medical Research Methodology
16. Binding Sites of Anticancer Drugs on Human Serum Albumin (HSA): A Review
    Pejman Molaei, Hanie Mahaki, Hamed Manoochehri, Hamid Tanzadehpanah · 2022 · Protein and Peptide Letters
17. Microenvironment and multiple myeloma spread
    Doménico Ribatti, Michele Moschetta, Angelo Vacca · 2014 · Thrombosis Research
18. Hematologic malignancies and thrombosis
    Francesca Elice, Francesco Rodeghiero · 2011 · Thrombosis Research
19. Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies
    Michael Medinger, Natalie Fischer, Alexandar Tzankov · 2010 · Journal of Oncology
20. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Jian Hou, Xin Du, Jie Jin, Zhen Cai, Fangping Chen, Dao-Bin Zhou, Li Yu, Xiaoyan Ke, Xiao Li, Depei Wu et al. · 2013 · Journal of Hematology & Oncology
21. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
    Holkova, Beata, Zingone, Adriana, Kmieciak, Maciej, Bose, Prithviraj, Badros, Ashraf Z., Voorhees, Peter M., Baz, Rachid, Korde, Neha, Lin, Hui-Yi, Chen, Jin-Qiu et al. · 2016 · Clinical Cancer Research
22. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis
    Ying Li, Tong YinHui, Zheng Yunliang, Haozhen Sun · 2017 · Oncotarget
23. New Agents in Multiple Myeloma: An Examination of Safety Profiles
    Sara Bringhen, Edwin de Wit, Meletios Athanasios Dimopoulos · 2017 · Clinical Lymphoma Myeloma & Leukemia
24. Tumour and microparticle tissue factor expression and cancer thrombosis
    Kathryn L. Date, Jessica Hall, John Greenman, Anthony Maraveyas, Leigh A. Madden · 2012 · Thrombosis Research
25. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide‐based regimens
    Tina Bagratuni, Efstathios Kastritis, Marianna Politou, Μαρία Ρούσσου, Efthimios Kostouros, Maria Gavriatopoulou, Evangelos Eleutherakis‐Papaiakovou, Nikolaos Kanellias, Evangelos Terpos, Meletios Athanasios Dimopoulos · 2013 · American Journal of Hematology
26. Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
    Donna M. Weber, Thorsten T. Graef, Mohamad A. Hussein, Ronald M. Sobecks, Gary John Schiller, Lisa C. Lupinacci, James S. Hardwick, Sundar Jagannath · 2012 · Clinical Lymphoma Myeloma & Leukemia
27. Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma
    Ted Wun, Richard H. R. White · 2010 · Thrombosis Research
28. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma
    J.A. Burzynski, Juan J. Toro, Rakhi Chhaganbhai Patel, Shuko Lee, Rebecca E. Greene, Jose Leonel Ochoa-Bayona, Christopher Raymond Frei, César O. Freytes · 2009 · Leukemia & lymphoma/Leukemia and lymphoma
29. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)
    Krönke, J, Kuchenbauer, F, Kull, M, Teleanu, V, Bullinger, L, Bunjes, D, Greiner, A, Kolmus, S, Köpff, S, Schreder, M et al. · 2017 · Leukemia
30. Immunomodulatory drugs in multiple myeloma
    Swati Andhavarapu, Vivek Roy · 2013 · Expert Review of Hematology
31. Complications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia
    Paul Gerard Guy Richardson, Jacob P. Laubach, Robert L Schlossman, Constantine S. Mitsiades, Kenneth Carl Anderson · 2010 · Journal of the National Comprehensive Cancer Network
32. Managing treatment-related peripheral neuropathy in patients with multiple myeloma
    Maria Teresa Petrucci, Laura Cesini, Sara Grammatico · 2016 · Blood and Lymphatic Cancer Targets and Therapy
33. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
    Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, Carolina Terragna, Paola Omedè, Antonio Pierangelo Palumbo, Sara Bringhen, Lorenzo De Paoli, Enrica Antonia Martino, Alessandra Larocca et al. · 2019 · Journal of Hematology & Oncology
34. Mechanisms of lenalidomide sensitivity and resistance
    Sergio Martínez-Høyer, Aly Karsan · 2020 · Experimental Hematology
35. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
    Kelly, Kevin R, Ailawadhi, Sikander, Siegel, David S, Heffner, Leonard T, Somlo, George, Jagannath, Sundar, Zimmerman, Todd M, Munshi, Nikhil C, Madan, Sumit, Chanan-Khan, Asher et al. · 2021 · The Lancet Haematology
36. Outcomes of primary refractory multiple myeloma and the impact of novel therapies
    Neil Majithia, S. Vincent Rajkumar, Martha Q. Lacy, Francis K. Buadi, Angela A. Dispenzieri, Morie Abraham Gertz, Suzanne R. Hayman, David Dingli, Prashant Kapoor, Yi L. Hwa et al. · 2015 · American Journal of Hematology
37. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma
    Jean El Cheikh, Roberto Crocchiolo, Sabine Fürst, Patrick Ladaique, Luca Castagna, Catherine Faucher, Angéla Granata, Claire Oudin, Claude Lemarié, Boris Calmels et al. · 2012 · Experimental Hematology
38. Lenalidomide long-term neurotoxicity
    Chiara Dalla Torre, Renato Zambello, Mario Cacciavillani, Marta Campagnolo, Tamara Berno, Alessandro Salvalaggio, Elena De March, Gregorio Barilà, Albano Lico, Marta Lucchetta et al. · 2016 · Neurology
39. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?
    Pieter Sonneveld, Edwin de Wit, Philippe Moreau · 2017 · Critical Reviews in Oncology/Hematology
40. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions
    Philippe Moreau, Edwin de Wit · 2017 · British Journal of Haematology
41. Risk of Rash Associated With Lenalidomide in Cancer Patients: A Systematic Review of the Literature and Meta-analysis
    Nardone, Beatrice, Wu, Shenhong, Garden, Benjamin C., West, Dennis P., Reich, Lilian M., Lacouture, Mario E. · 2013 · Clinical Lymphoma Myeloma and Leukemia
42. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
    the Korean Multiple Myeloma Working Party, Yeo‐Kyeoung Kim, Sang‐Kyun Sohn, Jae-Hoon Lee, Deok-Hwan Yang, Joonho Moon, Jae-Sook Ahn, Hyeoung‐Joon Kim, Je‐Jung Lee · 2009 · Annals of Hematology
43. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
    Meletios Athanasios Dimopoulos, Arlene S. Swern, J S Li, M. A. Hussein, Lilia Weiss, Yasir M. Nagarwala, Rachid Baz · 2014 · Blood Cancer Journal
44. Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
    Noémie Leblay, Ranjan Maity, Fajer Hasan, Paola E. Neri · 2020 · Frontiers in Oncology
45. Multiple myeloma
    Joan Bladé, María Teresa Cibeira, Carlos Fernández de Larrea, Laura Rosiñol · 2010 · Annals of Oncology
46. Treatment of plasma cell dyscrasias with lenalidomide
    Meletios Athanasios Dimopoulos, Efstathios Kastritis, S. Vincent Rajkumar · 2008 · Leukemia
47. How I treat elderly patients with myeloma
    Jayesh Mehta, Michèle Cavo, Seema Singhal · 2010 · Blood
48. Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy
    Tyler A. Scullen, Loredana Santo, Sonia Vallet, Mariateresa Fulciniti, Homare Eda, Diana D. Cirstea, Kishan J. Patel, Neeharika Nemani, Andrew Jenho Yee, Anuj Kumar Mahindra et al. · 2013 · Leukemia
49. Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment
    Asher Alban Chanan-Khan, Jesús F. San Miguel, Sundar Jagannath, Heinz Ludwig, Meletios Athanasios Dimopoulos · 2012 · Clinical Cancer Research
50. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide – A systematic review
    Fatimah Al‐Ani, José María Bastida, María‐Victoria Mateos, Martha Louzada · 2016 · Thrombosis Research
51. Strategies to improve patient-reported outcome completion rates in longitudinal studies
    Lene Kongsgaard Nielsen, Madeleine Trudy King, Sören Möller, Mary Jarden, Christen Lykkegaard Andersen, Henrik Frederiksen, Henrik Gregersen, Anja Klostergaard, Morten Steffensen, Per Trøllund Pedersen et al. · 2019 · Quality of Life Research
52. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide
    Andrew Jenho Yee, Parameswaran Hari, Raffaella Marcheselli, Anuj Kumar Mahindra, Diana D. Cirstea, Tyler A. Scullen, Jill N. Burke, Scott J. Rodig, Teru Hideshima, Jacob P. Laubach et al. · 2014 · British Journal of Haematology
53. Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma
    Mark Korthals, Nina Sehnke, Ralf Kronenwett, Thomas A. Schroeder, Tobias Strapatsas, Guido Kobbe, Rainer R. Haas, Roland R. Fenk · 2013 · Transplantation and Cellular Therapy
54. Second autologous transplant as salvage therapy in multiple myeloma
    Djordje Atanackovic, Georgia Schilling · 2013 · British Journal of Haematology
55. Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Shinsuke Iida, Takaaki Chou, Shinichiro Okamoto, Hirokazu Nagai, Kiyohiko Hatake, Hirokazu Murakami, Toshiyuki Takagi, Kazuyuki Shimizu, Henry S. H. Lau, Kenichi Takeshita et al. · 2010 · International Journal of Hematology
56. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
    Antonio Pierangelo Palumbo, Alessandra Larocca, P. Falco, Grazia Sanpaolo, Antonietta Pia Falcone, V Federico, Letizia Canepa, Monica Crugnola, Maurizio Genuardi, Valeria Magarotto et al. · 2010 · Leukemia
57. Role of tumour angiogenesis in haematological malignancies
    Michael Medinger, Jakob Robert Passweg · 2014 · Swiss Medical Weekly
58. Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries
    Roberto Josè Pessoa de Magalhães Filho, Edvan de Queiroz Crusoé, Eloísa Riva, Willen Bujan, Guilhermo Conte, Juan Ramon Navarro-Cabrera, Diana Katerine Garcia, Guilhermo e Quintero Vega, Jose Macias, Jose Willian Oliveros Alvear et al. · 2018 · Clinical Lymphoma Myeloma & Leukemia
59. New Drugs in Multiple Myeloma
    Chutima Kunacheewa, Robert Zygmunt Orlowski · 2019 · Annual Review of Medicine
60. The Role of Distinct Subsets of Macrophages in the Pathogenesis of MS and the Impact of Different Therapeutic Agents on These Populations
    Maedeh Radandish, Parvin Khalilian, Nafiseh Esmaeil · 2021 · Frontiers in Immunology
61. Venous thromboembolism in multiple myeloma: Current perspectives in pathogenesis
    Noppacharn Uaprasert, Peter Michael Voorhees, Nigel Mackman, Nigel S. Key · 2010 · European Journal of Cancer
62. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group
    Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, Eirini Katodritou, Αθανάσιος Παπαθεοδώρου, Anastasia G. Pouli, Marie‐Christine Kyrtsonis, Eurydiki Michalis, Xenophon Papanikolaou, Maria Aslani Gkotzamanidou et al. · 2013 · American Journal of Hematology
63. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy
    Téreza Coman, Emmanuel Bachy, Mauricette Michallet, Gèrard Socié, Madalina Uzunov, Jean Henri Bourhis, Simona Lapusan, Alain Brebion, S. Vigouroux, Sébastien Maury et al. · 2012 · Haematologica
64. Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study
    A. Gunther, P. Baumann, Renate Burger, Christian Kellner, Wolfram Klapper, Ralf Schmidmaier, Martin Gramatzki · 2015 · Haematologica
65. Clinical trials with anti‐angiogenic agents in hematological malignancies
    Medinger, Michael, Mross, Klaus · 2010 · Journal of Angiogenesis Research
66. Practical Management of Lenalidomide-Related Rash
    Sara Tinsley, Sandra E Kurtin, Jean Ridgeway · 2015 · Clinical Lymphoma Myeloma & Leukemia
67. Efficacy and safety of low‐dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome
    Qian‐Qian Cai, Chen Wang, Xinxin Cao, Hao Cai, Daobin Zhou, Jian Li · 2014 · European Journal Of Haematology
68. Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
    Jean‐Luc Harousseau, Martin H. Dreyling · 2009 · Annals of Oncology
69. Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma
    Brigitte Neuber, Isabelle Herth, Claudia Tolliver, Stefan Olaf Schönland, Ute Hegenbart, Dirk Hose, Mathias Witzens‐Harig, Anthony Dick Ho, Hartmut Goldschmidt, Bernard Klein et al. · 2011 · The Journal of Immunology
70. Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
    Ria, Roberto, Melaccio, Assunta, Racanelli, Vito, Vacca, Angelo · 2020 · Journal of Clinical Medicine
71. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
    Antonio Pierangelo Palumbo, Meletios Athanasios Dimopoulos, Jesús F. San Miguel, Jean‐Luc Harousseau, Michel Attal, Mohamad A. Hussein, Stefan Tobias Knop, Heinz Ludwig, Marie von Lilienfeld‐Toal, Pieter Sonneveld · 2008 · Blood Reviews
72. Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
    Robert Zygmunt Orlowski · 2013 · Seminars in Oncology
73. “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group
    Eirini Katodritou, Chrysanthi Vadikolia, Chrysavgi Lalagianni, Maria Kotsopoulou, Georgia Papageorgiou, Marie‐Christine Kyrtsonis, Panagiota Matsouka, Nikolaos C. Giannakoulas, Despoina S Kyriakou, Georgios Karras et al. · 2013 · Annals of Hematology
74. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma
    Adriana Rossi, Tomer Martin Mark, David S. Jayabalan, Paul J. Christos, Faiza Zafar, Karen A. Pekle, Roger Niles Pearse, Selina Chen‐Kiang, Morton Coleman, Rubén Niesvizky · 2013 · Blood
75. Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)
    Wai Man Liu, Jake Y. Henry, Brendan Meyer, J. Blake Bartlett, Angus George Dalgleish, Christine Galustian · 2009 · British Journal of Cancer
76. Novel approaches for reducing free light chains in patients with myeloma kidney
    Colin A. Hutchison, Joan Bladé, Paul Cockwell, Mark A. Cook, Mark Trehane Drayson, Jean‐Paul Fermand, Efstathios Kastritis, Robert A. Kyle, Nelson Leung, Sonia Pasquali et al. · 2012 · Nature Reviews Nephrology
77. Clinical characteristics of patients with relapsed multiple myeloma
    Meletios Athanasios Dimopoulos, Evangelos Terpos, Rubén Niesvizky, Antonio Pierangelo Palumbo · 2015 · Cancer Treatment Reviews
78. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
    James R. Berenson, Ori Yellin, T. Kazamel, James D. Hilger, Chen‐Li Cheng, A Cartmell, Thomas B. S. Woliver, Marshall S. Flam, Eric Bravin, Youram Nassir et al. · 2012 · Leukemia
79. Pomalidomide: New immunomodulatory agent with potent antiproliferative effects
    Paul Gerard Guy Richardson, Tomer Martin Mark, Martha Q. Lacy · 2013 · Critical Reviews in Oncology/Hematology
80. Lenalidomide for the treatment of relapsed and refractory multiple myeloma
    Güllü Görgün, Niels W.C.J. van de Donk, Richard W.J. Groen, Jana Jakubı́ková, Constantine S. Mitsiades, Teru Hideshima, Paul Gerard Guy Richardson, Nijhof, Raymakers, Henk M. Lokhorst et al. · 2012 · Cancer Management and Research
81. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study
    Jing Luo, Joshua J. Gagne, Joan E. Landon, Jerry Avorn, Aaron Seth Kesselheim · 2016 · European Journal of Cancer
82. Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma
    Anil Kumar Deshantri, Marcel H.A.M. Fens, Ruud W. J. Ruiter, Josbert M. Metselaar, Gert Storm, Louis van Bloois, Aida Varela-Moreira, Sanjay N. Mandhane, Tuna Mutis, Anton C. Martens et al. · 2019 · Journal of Controlled Release
83. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone
    Hong Chang, Allan Jiang, Connie X.Y. Qi, Young Trieu, Christine I. Chen, Donna Ellen Reece · 2010 · Leukemia & lymphoma/Leukemia and lymphoma
84. Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma
    Yvonne Adeduni Efebera, Sofia Qureshi, Suzanne Cole, Rima M. Saliba, Matteo Pelosini, Ronak M. Patel, Ebru Koca, Floralyn L. Mendoza, Michael L. Wang, Jatin J. Shah et al. · 2010 · Transplantation and Cellular Therapy
85. Lenalidomide: A new therapy for multiple myeloma
    Antonio Pierangelo Palumbo, Jesús F. San Miguel, Pieter Sonneveld, Philippe Moreau, Johannes W. Drach, Gareth John Morgan, Hermann Einsele · 2008 · Cancer Treatment Reviews
86. Multiple Myeloma as a Model for the Role of Bone Marrow Niches in the Control of Angiogenesis
    Doménico Ribatti, Beatrice Nico, Angelo Vacca · 2014 · International review of cytology
87. Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
    Eric M. Maiese, Claire Ainsworth, Jean-Gabriel Le Moine, Outi Ahdesmäki, Judith A. Bell, Emma Hawe · 2018 · Clinical Therapeutics
88. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: A systematic review
    Christoph Röllig, Thomas Illmer · 2009 · Cancer Treatment Reviews
89. AT ‐101 downregulates BCL 2 and MCL 1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and W aldenström macroglobulinaemia
    Aneel Paulus, Kasyapa S. Chitta, Sharoon Akhtar, David A. Personett, Kena C. Miller, Kevin J. Thompson, Jennifer M. Carr, Shaji Kunnathu Kumar, Vivek Roy, Stephen Maxted Ansell et al. · 2013 · British Journal of Haematology
90. Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization
    Qinjie Weng, Jiaying Wang, Jiajia Wang, Jing Wang, Fahmida Sattar, Zhikang Zhang, Jiahuan Zheng, Zijie Xu, Mengting Zhao, Xuan Liu et al. · 2018 · Cell Death and Disease
91. Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity
    N. Chen, Claudia Kasserra, Josephine F. Reyes, L. Liu, Henry S. H. Lau · 2012 · Cancer Chemotherapy and Pharmacology
92. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients
    Christine König, Martina Kleber, Heike Reinhardt, Stefan Tobias Knop, Ralph Wäsch, Monika Martha Engelhardt · 2013 · Annals of Hematology
93. Advances in therapy of multiple myeloma
    Joan Bladé, Laura Rosiñol · 2008 · Current Opinion in Oncology
94. Association between cancer types, cancer treatments, and venous thromboembolism in medical oncology patients.
    Michael Blake Streiff · 2013 · PubMed
95. Relationship between Treatment Effects on Progression-Free Survival and Overall Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis of Published Clinical Trial Data
    Shannon Cartier, Bin Zhang, Virginia M. Rosen, Victoria Zarotsky, J. Blake Bartlett, Pralay Mukhopadhyay, Samuel Wagner, Catherine Davis · 2015 · Oncology Research and Treatment
96. ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
    Paola E. Neri, Benjamin G. Barwick, David Jung, Jonathan C. Patton, Ranjan Maity, Inès Tagoug, Caleb K. Stein, Rémi Tilmont, Noémie Leblay, Sungwoo Ahn et al. · 2023 · Blood Cancer Discovery
97. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study
    Javier de la Rubia, Mónica Roig, Ángela Ibáñez, Inmaculada García, J A Esteban Vera, Carlos Aguilar, Raquel Del Campo, Nicolás González, Rafael Martínez, Luis Palomera et al. · 2010 · European Journal Of Haematology
98. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis
    Victor Hugo Jimenez-Zepeda, Virginia Jeanet Domínguez · 2009 · International Journal of Hematology
99. Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma
    Manh-Cuong Vo, Truc-Anh Thi Nguyen, Hyunju Lee, Thanh-Nhan Nguyen-Pham, Thangaraj Jaya Lakshmi, Sung‐Hoon Jung, Hyeoung‐Joon Kim, Je‐Jung Lee · 2016 · Experimental Hematology
100. Posttransplant maintenance therapy in multiple myeloma: the changing landscape
     Salyka M. Sengsayadeth, Florent Malard, Bipin N. Savani, Laurent Garderet, Mohamad Mohty · 2017 · Blood Cancer Journal